DTB Review: Three new drugs for the prevention of migraine

An overview is provided on three new monoclonal antibodies (erenumab, fremanezumab and galcanezumab) that target calcitonin gene-related peptide andare licensed for migraine prophylaxis in adults who have at least four migraine days per month.

Drug and Therapeutics Bulletin